{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:53:42Z","timestamp":1774968822266,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1038\/tpj.2013.47","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T11:04:25Z","timestamp":1389092665000},"page":"390-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT2A receptor"],"prefix":"10.1038","volume":"14","author":[{"given":"J M","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Newby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I M","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G K","family":"Isbister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"BFtpj201347_CR1","unstructured":"Australia's Health. The Twelfth Biennial Report of the Australian Institute of Health and Welfare. AIHW: Canberra, Australia, 2010."},{"key":"BFtpj201347_CR2","unstructured":"Health United States, 2012: with Special Feature on Emergency Care. National Center for Health Statistics: Hyattsville, MD, USA, 2013."},{"key":"BFtpj201347_CR3","unstructured":"Australian Statistics on Medicines 2010. Australian Government Department of Health and Ageing: Canberra, Australia, 2012."},{"key":"BFtpj201347_CR4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0022-3565(25)30202-8","volume":"193","author":"DT Wong","year":"1975","unstructured":"Wong DT, Bymaster FP, Horng JS, Molloy BB . A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine. J Pharmacol Exp Ther 1975; 193: 804\u2013811.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201347_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","volume":"420","author":"W Koek","year":"2001","unstructured":"Koek W, Vacher B, Cosi C, Assie MB, Patoiseau JF, Pauwels PJ et al. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur J Pharmacol 2001; 420: 103\u2013112.","journal-title":"Eur J Pharmacol"},{"key":"BFtpj201347_CR6","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1021\/jm070714l","volume":"50","author":"JL Maurel","year":"2007","unstructured":"Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B . High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. J Med Chem 2007; 50: 5024\u20135033.","journal-title":"J Med Chem"},{"key":"BFtpj201347_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3565(24)37788-2","volume":"287","author":"W Koek","year":"1998","unstructured":"Koek W, Patoiseau JF, Assie MB, Cosi C, Kleven MS, Dupont-Passelaigue E et al. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 1998; 287: 266\u2013283.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFtpj201347_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5694\/j.1326-5377.2007.tb01282.x","volume":"187","author":"GK Isbister","year":"2007","unstructured":"Isbister GK, Buckley NA, Whyte IM . Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007; 187: 361\u2013365.","journal-title":"Med J Aust"},{"key":"BFtpj201347_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.neuropharm.2008.08.034","volume":"55","author":"DL Murphy","year":"2008","unstructured":"Murphy DL, Fox MA, Timpano KR, Moya PR, Ren-Patterson R, Andrews AM et al. How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems. Neuropharmacology 2008; 55: 932\u2013960.","journal-title":"Neuropharmacology"},{"key":"BFtpj201347_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/07853890510037347","volume":"37","author":"N Norton","year":"2005","unstructured":"Norton N, Owen MJ . HTR2A: association and expression studies in neuropsychiatric genetics. Ann Med 2005; 37: 121\u2013129.","journal-title":"Ann Med"},{"key":"BFtpj201347_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0304-3940(01)01704-9","volume":"303","author":"C Minov","year":"2001","unstructured":"Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119\u2013122.","journal-title":"Neurosci Lett"},{"key":"BFtpj201347_CR12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/WNR.0b013e32832eb708","volume":"20","author":"A Illi","year":"2009","unstructured":"Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N et al. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009; 20: 1125\u20131128.","journal-title":"Neuroreport"},{"key":"BFtpj201347_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/(SICI)1096-8628(20000207)96:1<84::AID-AJMG17>3.0.CO;2-9","volume":"96","author":"A Serretti","year":"2000","unstructured":"Serretti A, Cusin C, Lorenzi C, Lattuada E, Lilli R, Smeraldi E . Serotonin-2A receptor gene is not associated with symptomatology of schizophrenia. Am J Med Genet 2000; 96: 84\u201387.","journal-title":"Am J Med Genet"},{"key":"BFtpj201347_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/(SICI)1096-8628(20000403)96:2<136::AID-AJMG2>3.0.CO;2-S","volume":"96","author":"I Massat","year":"2000","unstructured":"Massat I, Souery D, Lipp O, Blairy S, Papadimitriou G, Dikeos D et al. A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. Am J Med Genet 2000; 96: 136\u2013140.","journal-title":"Am J Med Genet"},{"key":"BFtpj201347_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ajmg.b.30642","volume":"147B","author":"C Vaquero-Lorenzo","year":"2008","unstructured":"Vaquero-Lorenzo C, Baca-Garcia E, Diaz-Hernandez M, Perez-Rodriguez MM, Fernandez-Navarro P, Giner L et al. Association study of two polymorphisms of the serotonin-2A receptor gene and suicide attempts. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 645\u2013649.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"BFtpj201347_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0920-9964(03)00126-9","volume":"69","author":"A Ertugrul","year":"2004","unstructured":"Ertugrul A, Kennedy JL, Masellis M, Basile VS, Jayathilake K, Meltzer HY . No association of the T102C polymorphism of the serotonin 2A receptor gene (HTR2A) with suicidality in schizophrenia. Schizophr Res 2004; 69: 301\u2013305.","journal-title":"Schizophr Res"},{"key":"BFtpj201347_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-244X-13-25","volume":"13","author":"TB Gonz\u00e1lez-Castro","year":"2013","unstructured":"Gonz\u00e1lez-Castro TB, Tovilla-Z\u00e1rate C, Ju\u00e1rez-Rojop I, Pool Garc\u00eda S, Vel\u00e1zquez-S\u00e1nchez MP, Genis A et al. Association of the 5HTR2A gene with suicidal behavior: case-control study and updated meta-analysis. BMC Psychiatry 2013; 13: 25.","journal-title":"BMC Psychiatry"},{"key":"BFtpj201347_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1096-8628(20001204)96:6<831::AID-AJMG27>3.0.CO;2-K","volume":"96","author":"B Bondy","year":"2000","unstructured":"Bondy B, Kuznik J, Baghai T, Schule C, Zwanzger P, Minov C et al. Lack of association of serotonin-2A receptor gene polymorphism (T102C) with suicidal ideation and suicide. Am J Med Genet 2000; 96: 831\u2013835.","journal-title":"Am J Med Genet"},{"key":"BFtpj201347_CR19","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","volume":"355","author":"MJ Arranz","year":"2000","unstructured":"Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615\u20131616.","journal-title":"Lancet"},{"key":"BFtpj201347_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1017\/S1461145701002711","volume":"5","author":"C Cusin","year":"2002","unstructured":"Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002; 5: 27\u201335.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj201347_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","volume":"45","author":"T Niitsu","year":"2013","unstructured":"Niitsu T, Fabbri C, Bentini F, Serretti A . Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183\u2013194.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"BFtpj201347_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1399-5618.2008.00598.x","volume":"10","author":"L Lattanzi","year":"2008","unstructured":"Lattanzi L, Danesi R, Lastella M, Mungai F, Di Paolo A, Tuccori M et al. Serotonin syndrome and the T102 \u2192C polymorphism of the 5-HT2A receptor: a case report. Bipolar Disord 2008; 10: 655\u2013656.","journal-title":"Bipolar Disord"},{"key":"BFtpj201347_CR23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1001\/archpsyc.61.11.1163","volume":"61","author":"GM Murphy Jr.","year":"2004","unstructured":"Murphy GM Jr., Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF . Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163\u20131169.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtpj201347_CR24","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1176\/appi.ajp.160.10.1830","volume":"160","author":"GM Murphy Jr.","year":"2003","unstructured":"Murphy GM Jr., Kremer C, Rodrigues HE, Schatzberg AF . Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830\u20131835.","journal-title":"Am J Psychiatry"},{"key":"BFtpj201347_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.wnf.0000177642.89888.85","volume":"28","author":"GK Isbister","year":"2005","unstructured":"Isbister GK, Buckley NA . The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005; 28: 205\u2013214.","journal-title":"Clin Neuropharmacol"},{"key":"BFtpj201347_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1176\/ajp.148.6.705","volume":"148","author":"H Sternbach","year":"1991","unstructured":"Sternbach H . The serotonin syndrome. Am J Psychiatry 1991; 148: 705\u2013713.","journal-title":"Am J Psychiatry"},{"key":"BFtpj201347_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1054\/mehy.2000.1047","volume":"55","author":"JW Radomski","year":"2000","unstructured":"Radomski JW, Dursun SM, Reveley MA, Kutcher SP . An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55: 218\u2013224.","journal-title":"Med Hypotheses"},{"key":"BFtpj201347_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","volume":"96","author":"EJ Dunkley","year":"2003","unstructured":"Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM . The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635\u2013642.","journal-title":"QJM"},{"key":"BFtpj201347_CR29","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2013. Oslo, Norway, 2012."},{"key":"BFtpj201347_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0006-8993(00)03020-1","volume":"890","author":"K Nisijima","year":"2001","unstructured":"Nisijima K, Yoshino T, Yui K, Katoh S . Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 2001; 890: 23\u201331.","journal-title":"Brain Res"},{"key":"BFtpj201347_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000094727","volume":"53","author":"M Kato","year":"2006","unstructured":"Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006; 53: 186\u2013195.","journal-title":"Neuropsychobiology"},{"key":"BFtpj201347_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1017\/S1461145707007985","volume":"11","author":"M Tanaka","year":"2008","unstructured":"Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11: 261\u2013267.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtpj201347_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1515\/CCLM.2007.181","volume":"45","author":"EM Penas-Lledo","year":"2007","unstructured":"Penas-Lledo EM, Dorado P, Caceres MC, de la Rubia A, Llerena A . Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs. Clin Chem Lab Med 2007; 45: 835\u2013838.","journal-title":"Clin Chem Lab Med"},{"key":"BFtpj201347_CR34","doi-asserted-by":"publisher","first-page":"e1001326","DOI":"10.1371\/journal.pmed.1001326","volume":"9","author":"KE Tansey","year":"2012","unstructured":"Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 2012; 9: e1001326.","journal-title":"PLoS Med"},{"key":"BFtpj201347_CR35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/sj.mp.4001502","volume":"9","author":"EJ Peters","year":"2004","unstructured":"Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP . Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879\u2013889.","journal-title":"Mol Psychiatry"},{"key":"BFtpj201347_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.npp.1300919","volume":"31","author":"Y Suzuki","year":"2006","unstructured":"Suzuki Y, Sawamura K, Someya T . Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006; 31: 825\u2013831.","journal-title":"Neuropsychopharmacology"},{"key":"BFtpj201347_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/hup.539","volume":"19","author":"RL Roberts","year":"2004","unstructured":"Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA . No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004; 19: 17\u201323.","journal-title":"Hum Psychopharmacol"},{"key":"BFtpj201347_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/sj.tpj.6500382","volume":"6","author":"T Sugai","year":"2006","unstructured":"Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T . The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006; 6: 351\u2013356.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201347_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00213-003-1430-1","volume":"167","author":"G Gerstenberg","year":"2003","unstructured":"Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003; 167: 443\u2013448.","journal-title":"Psychopharmacology (Berl)"},{"key":"BFtpj201347_CR40","unstructured":"Database of Single Nuclear Polymorphisms (dbSNP). Bethesda, MD, USA: National Centre for Biotechnology Information, National Library of Medicine. dbSNP accession: rs6313, (dbSNP Build ID:37.5). Available from http:\/\/www.ncbi.nlm.nih.gov\/SNP\/."},{"key":"BFtpj201347_CR41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s13181-010-0013-x","volume":"6","author":"AN Chan","year":"2010","unstructured":"Chan AN, Gunja N, Ryan CJ . A comparison of venlafaxine and SSRIs in deliberate self-poisoning. J Med Toxicol 2010; 6: 116\u2013121.","journal-title":"J Med Toxicol"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201347","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:31:12Z","timestamp":1746099072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["BFtpj201347"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2013.47","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]},"assertion":[{"value":"26 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}